Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: PAR-25-270
Official listed status: posted
Closing information: 2026-11-13 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Official federal synopsis lists an award ceiling of 1,050,000; applicant-level applicability requires full-NOFO review.
Applicant categories in federal synopsis: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Native American tribal governments (Federally recognized); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Special district governments; Independent school districts; City or township governments; Public housing authorities/Indian housing authorities; State governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); Native American tribal organizations (other than Federally recognized tribal governments); For profit organizations other than small businesses; Public and State controlled institutions of higher education; County governments
Federal synopsis
This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to 3 years support for studies to replicate the impact of the natural product on target engagement when used by humans, and assess whether there is an association between the degree of the impact on target engagement and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to engage the same target; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this …
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.